Provided by Tiger Trade Technology Pte. Ltd.

Apnimed

28.03
-0.5200-1.82%
Post-market: 27.58-0.4500-1.61%19:59 EDT
Volume:246.33K
Turnover:6.95M
Market Cap:1.12B
PE:-35.08
High:29.56
Open:28.60
Low:27.64
Close:28.55
52wk High:35.29
52wk Low:16.12
Shares:39.82M
Float Shares:12.00M
Volume Ratio:0.59
T/O Rate:2.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7990
EPS(LYR):-23.7581
ROE:--
ROA:-36.94%
PB:-3.67
PE(LYR):-1.18

Loading ...

Morningside Venture Investments Reports Apnimed Common Share Acquisition Valued at $5 Million

Reuters
·
Aug 06

Insider Move: Apnimed Director Makes Bold New Investment

TIPRANKS
·
Aug 04

Apnimed IPO Raises $220.8 Million at $16 Per Share

Reuters
·
Aug 04

Apnimed Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

GlobeNewswire
·
Aug 04

Apnimed Adopts New IPO-Era Bylaws with Advance Notice Rules for Shareholder Proposals

Reuters
·
Aug 04

Apnimed Director Paul J. Sekhri Acquires $200,000 in Common Shares

Reuters
·
Aug 04

Apnimed opens at $22.00, IPO priced at $16.00

TIPRANKS
·
Aug 01

NASDAQ Trade Halt Volatility Trading Pause at 11:49 Am

Reuters
·
Jul 31

Stock Track | Apnimed Soars 37.5% in Intraday Debut After Upsized IPO Priced at Top of Range

Stock Track
·
Jul 31

Sleep Apnea Pill Developer Apnimed Poised to Jump in Debut After Upsized IPO

Reuters
·
Jul 31

Apnimed Upsized IPO Priced at Top of Expectations

Dow Jones
·
Jul 31

NASDAQ Trade Halt Reason not Available at 04:00 Am

Reuters
·
Jul 31

Correction: Apnimed Prices $192 Million IPO

MT Newswires Live
·
Jul 31

Apnimed Inc - Pricing of IPO of 12,000,000 Shares of Its Common Stock at a Price to Public of $16.00 Per Share.

THOMSON REUTERS
·
Jul 31

Apnimed Announces Pricing of Upsized Initial Public Offering

THOMSON REUTERS
·
Jul 31

Apnimed - AD109 Generally Well-tolerated in Phase 3 Trials with Common Adverse Events Dry Mouth, Insomnia, Nausea

THOMSON REUTERS
·
Jul 14

Apnimed Announces FDA Acceptance of New Drug Application for Ad109, an Investigational Oral Pill to Treat Adults with Obstructive Sleep Apnea (osa)

THOMSON REUTERS
·
Jul 14

Apnimed - FDA Sets Pdufa Target Action Date of February 28, 2027 for AD109 Nda

THOMSON REUTERS
·
Jul 14